** Shares of women’s health firm Daré Bioscience DARE.O rise 88% to $4.72
** Stock set for best day in over 5 years, if gains hold
** Co says its medical device, Ovaprene, showed a pregnancy rate of about 9% among participants, in an ongoing late-stage study, in line with previous results
** Ovaprene is an investigational, hormone-free, monthly intravaginal device to prevent pregnancy
** An independent safety board reviewed the data and recommended the study continue without changes, co says
** Vaginal odor was the main side effect, leading 17% of participants to leave the study
** Ovaprene works by releasing a non-hormonal agent that slows sperm and uses a polymer barrier to block them from reaching the cervix
** Including session moves, stock up 50% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。